Abeona Therapeutics Inc FCF yield
Mi az Abeona Therapeutics Inc FCF yield?
A FCF yield az Abeona Therapeutics Inc - -85.62%
Mi a FCF yield meghatározása?
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
FCF yield a Health Care szektor a NASDAQ-on cégekben a Abeona Therapeutics Inc -hoz képest
Mit csinál Abeona Therapeutics Inc?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
fcf yield -hoz hasonló cégek Abeona Therapeutics Inc
- Mountain China Resorts () nak FCF yield -86.12% van
- Solstice Gold nak FCF yield -85.94% van
- Tasman Resources Ltd nak FCF yield -85.86% van
- Morphosys AG nak FCF yield -85.76% van
- U-Haul nak FCF yield -85.76% van
- Canoo nak FCF yield -85.63% van
- Abeona Therapeutics Inc nak FCF yield -85.62% van
- Catalyst Biosciences Inc nak FCF yield -85.57% van
- Macquarie Infrastructure nak FCF yield -85.42% van
- Amoeba S.A nak FCF yield -85.29% van
- Consolidated Communications Inc nak FCF yield -85.23% van
- Rafaella Resources nak FCF yield -85.21% van
- North Sea nak FCF yield -85.07% van